Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Eli Lilly and Company

LLY

HIGHLY FAVORABLE

May 21, 2026

Research Conclusion

At ~$1,007/share, Eli Lilly is one of the most compelling large-cap investment opportunities in public markets with probability-weighted fair value of ~$1,666/share (+66% upside). The bull case rests on tirzepatide generating $36.5B/year and accelerating, a pipeline extending efficacy (retatrutide 28.7%, orforglipron FDA-approved, MASH imminent), and an FCF inflection from $9B (FY2025) to $27B+ (FY2026E) to $52B+ (FY2028E). The market at $1,007 gives zero credit to retatrutide, multi-indication expansion, and the FCF inflection magnitude. ACCUMULATE aggressively ≤$1,100. HOLD $1,100-1,400. TRIM ≥$2,000.

Company Overview & Moat Assessment

Eli Lilly is a ~150-year-old Indianapolis pharmaceutical company transformed by tirzepatide (dual GIP+GLP-1 agonist) into the fastest-growing large pharma in history. Revenue surged from $28.3B (FY2021) to $65.2B (FY2025) to $19.8B in Q1 2026 (+56% YoY), with FY2026 guidance at $82-85B. The company has best-in-class efficacy (20-22% weight loss), the most advanced next-gen molecule (retatrutide 28.7% in Phase 3), and the first FDA-approved oral GLP-1 (orforglipron Q2 2026). CEO David Ricks since 2017 executed flawlessly through one of pharma's most successful launches. FCF is temporarily compressed by $23B+ manufacturing investment but will triple by FY2027-FY2028.

▲ Bull Case

  • ◆Multi-indication tirzepatide: The drug could generate $120-150B at peak with MASH ($8-15B/yr), CKD ($8-12B/yr), heart failure, sleep apnea, and PCOS adding incremental billions. Tirzepatide could become the highest-revenue drug in pharmaceutical history, shattering Humira's $22B peak.
  • ◆Retatrutide (28.7%) creates a second drug cycle. Approved ~FY2027, it leapfrogs competitors and extends LLY's efficacy leadership by 5-10 years, competing in populations where tirzepatide's 20-22% is insufficient. Peak revenue $30-60B — a second blockbuster from one R&D bet.
  • ◆FCF compounding unlocks capital return. At $75B+ FCF by FY2030, LLY funds pipeline AND returns $20-30B annually via buybacks/dividends. $20B annual buybacks retire 2%/yr mechanically adding EPS growth. Bull fair value: $2,100-3,000/share.

▼ Bear Case

  • ◆Net price decline accelerates beyond -10%/yr. IRA pressure and aggressive PBM negotiation force price cuts to maintain formulary access. Price declining -12 to -15%/yr with volume +25-30% only slows revenue growth and compresses consensus EPS. Bear impact: -20-35%.
  • ◆Pipeline execution disappoints. Retatrutide approval delayed 18+ months; MASH approval delayed; orforglipron ramp 50% below expectations. LLY dependent on tirzepatide alone longer than expected; growth decelerates to +15-20% by FY2027-2028. P/E de-rates from 28x to 18-20x. Bear impact: -20-35%.
  • ◆Long-term tirzepatide safety signal emerges. Label-changing finding (gallstones, lean mass loss, thyroid) after 3+ years triggers FDA review and revised labeling. Patient churn and physician caution reduce new starts significantly. Bear impact: -35-45% immediate; -60-70% if black box warning.
Primary Debate on Wall Street

“Central debate: Is beyond-obesity multi-indication expansion incremental or structural? Bulls argue tirzepatide is a metabolic disease drug (not obesity-only), with MASH/CKD/HF/sleep apnea as a second drug cycle within the molecule. TAM is $500B+ not $200B; stock deserves $1,500+. Bears contend payer coverage for adjacent indications will be restrictive, physician education slow, and new competitors competitive. FDA-to-commercial gaps larger than bulls model. Market currently prices the bear view (zero MASH/CKD/HF credit) while acknowledging obesity/T2D dominance. Resolution comes via: first MASH commercial quarter, first orforglipron quarterly data, first disclosed retatrutide prescription trends.”

Top Catalysts
  • ◆MASH (tirzepatide) FDA approval (FY2026-Q3 2026): +10-15% stock
  • ◆Retatrutide NDA submission (FY2026): +5-10% stock
  • ◆Orforglipron commercial results (Q3-Q4 2026): +5-15% stock
  • ◆Q2 2026 earnings / FY2026 FCF visibility (Jul 2026): +5-10% stock
  • ◆Retatrutide FDA approval (~FY2027): +15-25% stock
  • ◆CKD tirzepatide approval (FY2027-2028): +8-12% stock
  • ◆Annual guidance raise pattern (quarterly): +5-8% cumulative per quarter
Top Risks
  • ◆Tirzepatide safety signal (new black box): LOW-MEDIUM probability, HIGH magnitude (-30-50%)
  • ◆IRA biologics clock shortened to 9yr: LOW probability, HIGH magnitude (-20-40%)
  • ◆Net price decline accelerates >-10%/yr: MEDIUM probability, MEDIUM magnitude (-15-25%)
  • ◆Retatrutide Phase 3 safety signal: LOW probability, MEDIUM magnitude (-15-20%)
  • ◆Major PBM formulary exclusion: LOW-MEDIUM probability, MEDIUM magnitude (-10-15%)
  • ◆Competitive efficacy match by 2028: LOW probability, MEDIUM magnitude (-10-15%)

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/LLY/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.